Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection
Completed
Novartis Pharmaceuticals
Phase 2
This study will assess efficacy, safety , tolerability and PK in uncomplicated adult malaria
patients with P. vivax or P. falciparum infection after 3 day dosing with KAF156 at 400
mg/day (Part 1) and single dosing with KAF156 at 800mg (Part 2)
Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria
Completed
Medicines for Malaria Venture
Phase 2
This study aims to determine the most effective and tolerable dose at the shortest dosing
regimen of the investigational drug KAF156 in combination with a solid dispersion formulation
of lumefantrine (LUM-SDF) in adult/adolescent and pediatric patients with uncomplicated P.
falciparum malaria.
There is unmet medical need for anti-malarial treatment with new mechanism of action to
reduce probability of developing resistance, and for duration shorter than 3 days of
treatment and/or reduced pill burden.
Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria
Completed
Novartis Pharmaceuticals
Phase 2
This study aims to determine the most effective and tolerable dose at the shortest dosing
regimen of the investigational drug KAF156 in combination with a solid dispersion formulation
of lumefantrine (LUM-SDF) in adult/adolescent and pediatric patients with uncomplicated P.
falciparum malaria.
There is unmet medical need for anti-malarial treatment with new mechanism of action to
reduce probability of developing resistance, and for duration shorter than 3 days of
treatment and/or reduced pill burden.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.